BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
BICYCLE THERAPEUTICS PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.54+0.08 (+2.17%)
Close on Oct 19, 2026
- Market cap
- $246.76M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$4.64 (−56.73%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BICYCLE THERAPEUTICS PLC grew revenue 217.4% to $61.21M over the twelve months to Jun 30, 2026. Free cash flow was -$208.28M.
Revenue
$61.21M
+217.4% vs. a year earlier
Operating income
-$210.30M
TTM Q2 2026
Free cash flow
-$208.28M
TTM Q2 2026
EPS, diluted
-$2.73
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $246.76M
- P/E ratio
- –
- Price to sales
- 4.03
- Price to book
- 0.48
- Dividend yield
- 0.00%
- Free cash flow yield
- -84.40%
Fundamentals
- Revenue
- $61.21M
- Net income
- -$190.41M
- EPS, diluted
- -$2.73
- Free cash flow
- -$208.28M
- Book value per share
- $7.31
- Diluted shares
- 70M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$61.21M+217.4% YoY
Operating income
-$210.30M
Net income
-$190.41M
EPS, diluted
-$2.73
Free cash flow
-$208.28M
Reported periodTrailing twelve months